Tango Therapeutics (TNGX) to Release Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Tango Therapeutics to post earnings of ($0.3182) per share and revenue of $0.50 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Price Performance

TNGX opened at $19.26 on Friday. The company’s 50-day moving average is $14.29 and its 200 day moving average is $10.66. Tango Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $21.82. The firm has a market capitalization of $2.75 billion, a P/E ratio of -22.14 and a beta of 1.76.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Tango Therapeutics in a research report on Thursday, March 5th. Guggenheim lifted their target price on shares of Tango Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Wedbush upped their target price on Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Finally, Piper Sandler lifted their price target on Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $19.50.

Insiders Place Their Bets

In related news, insider Adam Crystal sold 20,251 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $15.00, for a total value of $303,765.00. Following the sale, the insider owned 112,622 shares of the company’s stock, valued at approximately $1,689,330. The trade was a 15.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $374,162.94. Following the completion of the transaction, the director owned 1,629,254 shares in the company, valued at approximately $19,974,654.04. The trade was a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 133,884 shares of company stock valued at $1,724,622. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Tango Therapeutics

Hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. grew its stake in shares of Tango Therapeutics by 322.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock worth $93,986,000 after acquiring an additional 8,096,924 shares during the period. Caligan Partners LP bought a new stake in Tango Therapeutics in the 4th quarter valued at about $33,047,000. Goldman Sachs Group Inc. raised its stake in Tango Therapeutics by 227.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,942,414 shares of the company’s stock valued at $43,790,000 after acquiring an additional 3,432,939 shares during the period. Logos Global Management LP lifted its holdings in Tango Therapeutics by 342.1% during the fourth quarter. Logos Global Management LP now owns 4,200,000 shares of the company’s stock valued at $37,212,000 after purchasing an additional 3,250,000 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP purchased a new stake in Tango Therapeutics during the third quarter valued at about $25,924,000. 78.99% of the stock is currently owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.